Comparative Pharmacology
Head-to-head clinical analysis: VIBATIV versus XERAVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VIBATIV versus XERAVA.
VIBATIV vs XERAVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lipoglycopeptide antibiotic that inhibits cell wall synthesis by binding to the D-Ala-D-Ala terminus of peptidoglycan precursors, blocking transglycosylation and transpeptidation. Also disrupts membrane potential and increases membrane permeability.
Eravacycline is a tetracycline-class antibacterial that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from attaching to the A-site. It exhibits activity against a broad range of Gram-positive, Gram-negative, and anaerobic bacteria, including many tetracycline-resistant strains due to modifications circumventing common resistance mechanisms.
10 mg/kg intravenously once every 24 hours, infused over 60 minutes for 7 to 14 days.
200 mg intravenously over 60 minutes every 12 hours
None Documented
None Documented
Terminal elimination half-life is approximately 177 hours (7.4 days), supporting once-daily dosing.
Terminal elimination half-life is approximately 42 hours (range 30-60 hours) in healthy subjects; prolonged in elderly patients and those with severe hepatic impairment.
Primarily renal excretion as unchanged drug (approximately 93% of dose recovered in urine; <5% in feces).
Fecal (approximately 80-90% as unchanged drug); renal (less than 1% as unchanged drug).
Category C
Category C
Antibiotic
Antibiotic